MİDE ADENOKARSİNOMLARINDA PRİMER TÜMÖR VE KARACİĞER METASTAZLARININ FDG PET/BT PARAMETRELERİNİN KARŞILAŞTIRILMASI
Öz
Mide
kanserinde evreleme, yeniden evreleme ve tedaviye yanıt değerlendirme amacı ile
[18F]-2-floro-2-deoksi-D-glukoz (FDG) pozitron emisyon tomografisi
(PET)/bilgisayarlı tomografi (BT) görüntüleme yapılmaktadır. FDG PET/BT
görüntülemede, primer tümörün ve metastazlarının metabolik parametreleri olan
maksimum standart uptake değeri (SUVmaks) ve tümör lezyon glikolizi (TLG)
değerlendirilmektedir. Bu retrospektif çalışmada evreleme amacı ile FDG PET/BT
görüntülemeleri yapılan opere olmamış mide adenokarsinomlu hastalarda primer tümörün
ve karaciğer metastazlarının metabolik parametrelerini elde etmeyi ve
karşılaştırmayı amaçladık. Çalışmaya 11 erişkin olgu (altı kadın, beş erkek)
dahil edildi. Primer mide tümörlerinin ve karaciğer metastazlarının (n=24) SUVmaks
ve TLG değerleri elde edildi ve independent sample t-test yapılarak
karşılaştırıldı. Primer mide tümörlerinin ve karaciğer metastazlarının ortalama
SUVmaks değerleri sırasıyla 8.3±3.3 ve 7.6±1.8 olarak bulundu (P<0.05). Primer mide tümörlerinin ve karaciğer
metastazlarının ortalama TLG değerleri sırasıyla 84.7±60.2 ve 127.9±39.7 olarak
bulundu (P<0.05). Primer mide tümörü ve karaciğer metastazlarının FDG PET/BT
ile elde edilen metabolik parametreleri arasında anlamlı farklılık
saptanmıştır. Karaciğer metastazlarına ait ortalama TLG değeri, primer tümörlerin
ortalama TLG değerinden daha yüksek çıktığı için, bu olguların FDG PET/BT
incelemesi yapılırken SUVmaks yanında TLG değerlerinin de dikkate alınmasının değerlendirmeye
önemli katkı sağlayacağı düşünülmüştür. Primer mide malignitesinin ve karaciğer
metastazlarının metabolik parametrelerini elde etmede FDG PET/BT etkin bir
yöntemdir.
Anahtar Kelimeler
Fluorodeoksiglukoz F18 pozitron-emisyon tomografi/bilgisayarlı tomografi mide neoplazmları neoplazm metastazları karaciğer
Kaynakça
- 1. Hopkins S, Yang GY. (2011). FDG PET imaging in the staging and management of gastric cancer. J Gastrointest Oncol; 2(1):39–44.
- 2. Lim JS, Yun MJ, Kim MJ, Hyung WJ, Park MS, Choi JY, Kim TS, Lee JD, Noh SH, Kim KW. (2006). CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics; 26(1):14–56.
- 3. Alobthani G, Romanov V, Isohashi K, Matsunaga K, Watabe T, Kato H, Tatsumi M, Shimosegawa E, Hatazawa J. (2018). Value of 18F-FDG PET/CT in discrimination between indolent and aggressive non-Hodgkin's lymphoma: A study of 328 patients. Hell J Nucl Med; 21(1):7−14.
- 4. Singh D, Miles K. (2012). Multiparametric PET/CT in oncology. Cancer Imaging; 12:336−44.
- 5. d'Amico A. (2015). Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy. Radiol Med; 120(4):345−51.
- 6. Satoh Y, Nambu A, Ichikawa T, Onishi H. (2014). Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. BMC Cancer; 14:525.
- 7. Altini C, Niccoli Asabella A, Di Palo A, Fanelli M, Ferrari C, Moschetta M, Rubini G. (2015). 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography. Medicine (Baltimore); 94(20):e864.
- 8. Soret M, Bacharach SL, Buvat I. (2007). Partial-volume effect in PET tumor imaging. J Nucl Med; 48(6):932−45.
- 9. Lee SY, Seo HJ, Kim S, Eo JS, Oh SC. (2018). Prognostic significance of interim 18 F-fluorodeoxyglucose positron emission tomography-computed tomography volumetric parameters in metastatic or recurrent gastric cancer. Asia Pac J Clin Onco; 14(5):e302-e309.
- 10. Lim SM, Kim H, Kang B, Kim HS, Rha SY, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, Jung M. (2016). Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Ann Nucl Med; 30(4):279–86.
- 11. Woff E, Hendlisz A, Ameye L, Garcia C, Kamoun T, Guiot T, Paesmans M, Flamen P. (2018). Validation of metabolically active tumor volume and total lesion glycolysis as 18F-FDGPET/CT–derived prognostic biomarkers in chemorefractory metastatic colorectal cancer. J Nucl Med; doi: 10.2967/jnumed.118.210161. [Epub ahead of print]
- 12. Grut H, Dueland S, Line PD, Revheim ME. (2018). The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging; 45(2):218−25.
COMPARISON OF THE FDG PET/CT PARAMETERS OF PRIMARY TUMORS AND LIVER METASTASES IN CASES WITH GASTRIC ADENOCARCINOMAS
Öz
Abstract
[18F]-2-fluoro-2-deoxy-D-glucose
(FDG) positron
emission tomography (PET)/ computed tomography (CT) imaging is being performed
for staging, restaging and evaluation of response to treatment in gastric
cancer. In FDG PET/CT imaging, metabolic parameters of the primary tumors and
their metastases, namely the maximum standard uptake value (SUVmax) and the tumor
lesion glycolysis (TLG) are evaluated. In this retrospective study, we aimed to
obtain and compare the metabolic parameters of the primary tumors and their
liver metastases in patients with gastric cancer who underwent FDG
PET/CT imaging and who didn’t undergo surgery. Eleven patients (six
females, five males) were included in the study. SUVmax and ve TLG values
of the primary tumors and their liver metastases (n=24) were obtained and
compared using independent sample t-test. The mean SUVmax of the primary
gastric tumors and their liver metastases were 8.3±3.3 ve 7.6±1.8, respectively
(P<0.05). The mean TLG of the
primary gastric tumors and their liver metastases were 84.7±60.2 ve 127.9±39.7,
respectively (P<0.05). There were significant differences between metabolic
parameters of the primary tumors and their liver metastases. Since the
mean TLG value of the liver metastases were higher than that of the primary
tumor, taking TLG values into account beside SUVmax values were considered to make
significant contribution to FDG PET/CT evaluation of these cases. FDG PET/CT is
an effective tool in obtaining metabolic parameters of primary gastric
malignancies and their liver metastases.
Anahtar Kelimeler
Fluorodeoxyglucose F18 positron-emission tomography/computed tomography stomach neoplasms neoplasm metastasis liver
Kaynakça
- 1. Hopkins S, Yang GY. (2011). FDG PET imaging in the staging and management of gastric cancer. J Gastrointest Oncol; 2(1):39–44.
- 2. Lim JS, Yun MJ, Kim MJ, Hyung WJ, Park MS, Choi JY, Kim TS, Lee JD, Noh SH, Kim KW. (2006). CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics; 26(1):14–56.
- 3. Alobthani G, Romanov V, Isohashi K, Matsunaga K, Watabe T, Kato H, Tatsumi M, Shimosegawa E, Hatazawa J. (2018). Value of 18F-FDG PET/CT in discrimination between indolent and aggressive non-Hodgkin's lymphoma: A study of 328 patients. Hell J Nucl Med; 21(1):7−14.
- 4. Singh D, Miles K. (2012). Multiparametric PET/CT in oncology. Cancer Imaging; 12:336−44.
- 5. d'Amico A. (2015). Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy. Radiol Med; 120(4):345−51.
- 6. Satoh Y, Nambu A, Ichikawa T, Onishi H. (2014). Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. BMC Cancer; 14:525.
- 7. Altini C, Niccoli Asabella A, Di Palo A, Fanelli M, Ferrari C, Moschetta M, Rubini G. (2015). 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography. Medicine (Baltimore); 94(20):e864.
- 8. Soret M, Bacharach SL, Buvat I. (2007). Partial-volume effect in PET tumor imaging. J Nucl Med; 48(6):932−45.
- 9. Lee SY, Seo HJ, Kim S, Eo JS, Oh SC. (2018). Prognostic significance of interim 18 F-fluorodeoxyglucose positron emission tomography-computed tomography volumetric parameters in metastatic or recurrent gastric cancer. Asia Pac J Clin Onco; 14(5):e302-e309.
- 10. Lim SM, Kim H, Kang B, Kim HS, Rha SY, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, Jung M. (2016). Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Ann Nucl Med; 30(4):279–86.
- 11. Woff E, Hendlisz A, Ameye L, Garcia C, Kamoun T, Guiot T, Paesmans M, Flamen P. (2018). Validation of metabolically active tumor volume and total lesion glycolysis as 18F-FDGPET/CT–derived prognostic biomarkers in chemorefractory metastatic colorectal cancer. J Nucl Med; doi: 10.2967/jnumed.118.210161. [Epub ahead of print]
- 12. Grut H, Dueland S, Line PD, Revheim ME. (2018). The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging; 45(2):218−25.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Bölüm | Araştırma Makalesi |
| Yazarlar | |
| Yayımlanma Tarihi | 1 Eylül 2019 |
| Yayımlandığı Sayı | Yıl 2019Cilt: 4 Sayı: 2 |
